News for Royalty Pharma plc (RPRX)

**media[552844]**

PR NewswireDUBLIN, Feb. 26, 2025 YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025.

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may face under the new Trump...

Robust market share with approximately 51% of all royalty transactions from 2020 through 2024.Portfolio includes royalties on 15 therapies with end-market sale

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX stock is a Buy.

On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, made a strategic decision to reduce its holdings in Royalty Pharma PLC (RPRX) by

Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Royalty Pharma Fourth Quarter Earnings Conference.

Royalty Pharma partners with Biogen, investing $250M in groundbreaking Phase 3 drug litifilimab for lupus.

Portfolio Receipts: $2.8 billion for 2024, representing 13% growth in Royalty Receipts.2025 Portfolio Receipts Guidance: Expected to be between $2.9 billion an

The following slide deck was published by Royalty Pharma plc in conjunction with their 2024 Q4 earnings call.

Earnings Call Insights: Royalty Pharma (NASDAQ:RPRX) Q4 2024Management ViewCEO Pablo Legorreta highlighted strong 2024 performance, reporting $2.8 billion...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ETCompany ParticipantsGeorge Grofik - SVP, Head, Investor...

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

**media[537513]**

XOMA Royalty Corporation's portfolio includes riskier assets, impacting its stability. Find out why XOMA stock’s high-risk profile may not suit all investors.

Patient Capital Management's Opportunity Equity Strategy surpassed the market to end up 26.5%, 150bps ahead of the S&P 500’s 25.0%. Click here to read the full fund letter.

PR NewswireWALTHAM, Mass., Jan. 13, 2025 ”“ Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pe

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday. Shares of TD Synnex Corp SNX rose sharply in today's session after the comp...